Using Brazilian ARV procurement data from 2001 to 2005, the authors concluded that while Brazil was able to obtain considerable discounts from originator companies, locally produced ARV prices remained higher than those of the global generic market and presented an increasing trend.
← all excerpts
Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
1
—
—